RNTX vs. ZNTL, ENTX, ONCY, IKT, OVID, SRZN, IRD, LFVN, SLGL, and EXOZ
Should you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Zentalis Pharmaceuticals (ZNTL), Entera Bio (ENTX), Oncolytics Biotech (ONCY), Inhibikase Therapeutics (IKT), Ovid Therapeutics (OVID), Surrozen (SRZN), Opus Genetics (IRD), Lifevantage (LFVN), Sol-Gel Technologies (SLGL), and eXoZymes (EXOZ). These companies are all part of the "pharmaceutical products" industry.
Rein Therapeutics vs. Its Competitors
Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.
Rein Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.
90.9% of Rein Therapeutics shares are held by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Rein Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Zentalis Pharmaceuticals' return on equity of -51.62% beat Rein Therapeutics' return on equity.
Zentalis Pharmaceuticals presently has a consensus target price of $5.84, indicating a potential upside of 267.30%. Rein Therapeutics has a consensus target price of $10.00, indicating a potential upside of 669.23%. Given Rein Therapeutics' higher possible upside, analysts clearly believe Rein Therapeutics is more favorable than Zentalis Pharmaceuticals.
Zentalis Pharmaceuticals has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Rein Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.
In the previous week, Rein Therapeutics had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for Rein Therapeutics and 2 mentions for Zentalis Pharmaceuticals. Rein Therapeutics' average media sentiment score of 0.63 beat Zentalis Pharmaceuticals' score of 0.62 indicating that Rein Therapeutics is being referred to more favorably in the news media.
Summary
Rein Therapeutics beats Zentalis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Rein Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rein Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RNTX) was last updated on 10/15/2025 by MarketBeat.com Staff
